Endpoints of drug discovery for menopausal vasomotor symptoms: interpretation of data from a proxy of disease.
Prelle K, Igl BW, Obendorf M, Girbig D, Lehmann T, Patchev VK.
Prelle K, et al. Among authors: patchev vk.
Menopause. 2012 Aug;19(8):909-15. doi: 10.1097/gme.0b013e318245533f.
Menopause. 2012.
PMID: 22473248
METHODS: Using telemetric recordings in a rat model of estrogen deficit-induced vasomotor dysregulation, we compared the long- and short-term effects of estrogen supplementation and treatment with neuropharmaceuticals (venlafaxine, desvenlafaxine, fluoxetine, agomelatine, …
METHODS: Using telemetric recordings in a rat model of estrogen deficit-induced vasomotor dysregulation, we compared the long- and short- …